nach oben

International Urology and Nephrology

Erschienen in:

09.12.2019 | Nephrology - Original Paper

Adjunctive acetazolamide therapy for the treatment of Bartter syndrome

verfasst von: Mojgan Mazaheri, Farahnak Assadi, Simin Sadeghi-Bojd

Erschienen in: International Urology and Nephrology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bartter syndrome is a rare hereditary salt-losing tubulopathy caused by mutations of several genes in the thick ascending limb of Henle’s loop, characterized by polyuria, hypokalemic metabolic alkalosis, growth retardation and normal blood pressure. Cyclooxygenase inhibitors, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors are currently used to treat electrolyte derangements, but with poor response. Whether treatment with acetazolamide, a carbonic-anhydrase inhibitor, would result in better clinical outcomes is unknown.

Methods

We randomly assigned children with Bartter syndrome in a 1:1 ratio to either receive indomethacin, enalapril, and spironolactone or indomethacin, enalapril, and spironolactone plus acetazolamide once daily in the morning for 4 weeks. After 2 days of washout, participants crossed over to receive the alternative intervention for 4 weeks. The present study examines the serum bicarbonate lowering effect of acetazolamide as an adjunctive therapy in children with Batter syndrome.

Results

Of the 43 patients screened for eligibility, 22 (51%), between the ages 6 and 42 months, were randomized to intervention. Baseline characteristics were similar between the two groups. Addition of acetazolamide for a period of 4 weeks significantly reduced serum bicarbonate and increased serum potassium levels, parallel with a reduction in serum aldosterone and plasma renin concentration. The 24-h urine volume, sodium, potassium, and chloride decreased significantly.

Conclusion

Our data define a new physiologic and therapeutic role of acetazolamide for the management of children with Bartter syndrome.

Bartter FC, Pronove P, Gill JR, MacCardle RC (1962) Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am J Med 33:811–828CrossRef

Cunha TDS, Heilberg IP (2018) Bartter syndrome: causes, diagnosis, and treatment. Int J Nephrol Renovasc Dis 11:291–301CrossRef

Seyberth HW, Weber S, Komhoff M (2017) Bartter’s and Gitelman’s syndrome. Curr Opin Pediatr 29:179–186CrossRef

Batter FC, Gill JR, Frolich JC, Bowden RE, Taylor AA, Keiser HR et al (1976) Prostaglandins are overproduced by the kidney and mediate hyperreninemia in Bartter’s syndrome. Trans Assoc Am Phys. 89:77–91

Boone M, Dean PMT (2008) Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 456:1005–1024CrossRef

Ares GR, Gaceres PS, Ortiz PA (2011) Molecular regulation of NKCC2 in the thick ascending limb. Am J Physiol Renal Physiol 301:F1143–F1159CrossRef

Simon DB, Karet FE, Hamdam JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter’s syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na–K–2Cl cotransporter NKCC2. Nat Genet 13:183–188CrossRef

Carmosino M, Procino G, Svelto M (2012) Na+ -K+ -2Cl–cotransporter type 2 trafficking and activity: the role of interacting proteins. Bil Cell 104:201–221CrossRef

Simon DB, Karet EE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H et al (1996) Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nati Genet 14:152–156CrossRef

10.

Seyes E, Andrini O, Kecj M, Mansour-Hendill L, Courand PY, Simin C et al (2017) Clinical and genetic spectrum of Bartter syndrome type 3. J Am Soc Nephrol 28:2540–2552CrossRef

11.

Simon DB, Binda RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R et al (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type 111. Nat Genet 117:171–178CrossRef

12.

Dane B, Yayla M, Dane C (2007) Prenatal diagnosis of Bartter syndrome with biochemical examination of amniotic fluid: case report Fetal Diag Ther 22:206–208

13.

Komhoff M, Laghmani K (2017) Pathophysiology of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 26:419–425CrossRef

14.

Najafi M, Koerdi-Tamandani DM, Behjati F, Sadeghi-Bojd S, Bakey Z, Karimiani EG et al (2019) Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Batter syndrome and proposition of an algorithm for clinical differential diagnosis. Orphanet J Rare Dis 14:41. https://doi.org/10.1186/s13023-018-0981-5 CrossRefPubMedPubMedCentral

15.

Brikenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I et al (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314CrossRef

16.

Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K et al (2008) Molecular analysis of digenetic inheritance in Bartter syndrome with sensonrineual deafness. J Med Genet 45:182–186CrossRef

17.

Laghmani K, Beck BB, Yang S-S, Seaayfan E, Wenzel A, Reusch B et al (2016) Polyhydramnios, transient antenatal Bartter’s syndrome, and MAGED2 mutations. N Engl J Med 374:1853–1863CrossRef

18.

Watanable S, Fukumoto S, Chang H, Takeuch Y, Hasegawa Y, Okazaki R et al (2002) Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet 360:692–694CrossRef

19.

Gasongo G, Greebaum LA, Neil O, Kwon T, Macher MA, Maisin A et al (2019) Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome. Pediatr Nephrol 34:679–684CrossRef

20.

Reinalter SC, Jecj N, Brochhausen C, Watzer B, Nusing RM, Seyberth HW et al (2002) Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 62:253–260CrossRef

21.

Nascimento CLP, Garcia CL, Schvartsman BGS, Vaisbich MH (2014) Treatment of Bartter syndrome, unsolved issue. J Pediatr 90:512–517CrossRef

22.

Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858-563CrossRef

23.

White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX et al (2007) Risk of cardiovascular events in patients receiving celecoxib: a metaanalysis of randomized clinical trials. Am J Cardiol 99:91–98CrossRef

24.

Preisig PA, Toto RD, Alpern RJ (2005) Carbonic anhydrase inhibitors. Renal Physiol 10:136–159

25.

Assadi F (2005) Acetazolamide for prevention of contrast-induce nephropathy: a new use for an old drug. Pediat Cardiol 27:238–242CrossRef

26.

Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–663CrossRef

27.

Altman DG, Anderson PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492–1495CrossRef

28.

Assadi F (2011) A practical approach to metabolic alkalosis. In: Elzouki AY, Harfi HA, Nazer H (eds) Textbook of clinical pediatrics, 2nd edn. Springer, New York, pp 2671–2676

29.

Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL (2013) Acetazolamide in critically ill neonates with metabolic alkalosis. Ann Pharmacother 47:1130–1135CrossRef

30.

Lopez C, Alcaraz AJ, Toledo B, Cortejoso L, Gil-Ruitz MA (2016) Acetazolamide therapy for metabolic alkalosis in pediatric intensive care patients. Pediatri Crit Care Med 17:e551–e555CrossRef

31.

Peixoto AJ, Alpern RJ (2013) Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis 61:822–827CrossRef

32.

Bar A, Cies J, Stapleton K, Tauber D, Chopra A, Shore PM (2015) Acetazolamide therapy for metabolic alkalosis in critically ill pediatric patients. Pediatr Crit Care Med 16:3e4-4CrossRef

33.

Zingerman B, Herman-Edelstein M, Eman A, Bar Sheshet Itach S, Ori Y, Rozen-Zvi B et al (2015) Effect of Acetazolamide on obesity-induced glomerular hyperfiltration: a randomized control trail. Plos One 10(9):e0137163. https://doi.org/10.1371/journal.pone.0137163 CrossRefPubMedPubMedCentral

34.

Yeyati NL, Alternberg GA, Adrogue HJ (1992) Mechanism of acetazolamide-induced rise in renal vascular resistance assessed in the dog whole kidney. Ren Physiol Biochem 15:99–105PubMed

35.

Skott P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH (1989) Theacute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. Scand J Clin Lab Invest 49:583–587CrossRef

36.

Slomowitz LA, Bergamo R, Hirschberg R, Grosvenor M, Kopple JD (1996) Enalapril attenuated the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Am J Nephrol 16:315–319CrossRef

37.

Hannedouche T, Lazzo M, Delgado AG, Boilard C, Lacour B, Grunfeld JP (1991) Feedback mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients. Clin Sci 81:457–464CrossRef

38.

Galler M, Backenroth R, Folkert VW, Schlondorff D (1982) Effect of converting enzyme inhibitors on prostaglandin synthesis by isolated glomeruli and aortic strips from rats. J Pharmacol Exp Ther 220:23–28PubMed

39.

Maisey DN, Brown RD (1981) Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J 283:1527–1529CrossRef

40.

Dorris R, Olivia JV, Rodman T (1964) Dichlorphenamide, a potent carbonic anhydrase inhibitor: effect on alveolar ventilation, ventilation-perfusion relationships and diffusion in patients with chronic lung disease. Am J Med 36:79–86CrossRef

Titel: Adjunctive acetazolamide therapy for the treatment of Bartter syndrome
verfasst von: Mojgan Mazaheri
Farahnak Assadi
Simin Sadeghi-Bojd
Publikationsdatum: 09.12.2019
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2020
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02351-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

A novel use of attenuation value (Hounsfield unit) in non-contrast CT: diagnosis of pyonephrosis in obstructed systems

Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria

Prostatic epithelial cells and their high expressions of CKIP-1 affect the TGF-β1 expression levels which might reduce the scar formation in remodeling stage at prostatic urethral wounds after wound repair

The epidemiology and role of surgery in the treatment of urethral clear cell carcinoma

HPV infection in urology practice